In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioForm targets $115m IPO (initial public offering) for product push:

This article was originally published in Clinica

Executive Summary

Plastic surgery specialist BioForm Medical has filed for an initial public offering that could boost funds by $115m. The firm is looking to finance the development of its Radiesse injectable dermal filler, which received FDA pre-market approvals in December 2006 for the treatment of facial lipoatrophy - facial fat loss - in patients with HIV and for cosmetic correction of wrinkles. The San Mateo, California-based company will also use a portion of the offering proceeds to gain US regulatory approval of its varicose vein treatment Aethoxysklerol (currently in Phase III clinical trials in the US) and BioGlue, a surgical adhesive for use in browplasty, which is in early-stage human trials. BioForm holds exclusive US distribution rights to Aethoxysklerol and exclusive US and Canadian distribution rights to BioGlue for medical aesthetic applications.

You may also be interested in...

ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva

The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.

FDA Sets New Restrictions For Authorized N95 Decontamination Systems

After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.

Biden Signs COVID-19 Relief EO To Expand And Accelerate Testing, Fill PPE Shortages

Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts